Intellia Therapeutics: cross-border access for the specialty portfolio

Quick orientation

Intellia Therapeutics, Inc. is a US clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on in vivo and ex vivo CRISPR/Cas9 gene-editing therapies. Intellia is one of the leading in vivo gene-editing platforms, with lipid nanoparticle delivery of CRISPR/Cas9 machinery directly to the liver in its lead candidates. The company is partnered with Regeneron on hereditary transthyretin amyloidosis (hATTR) and certain other indications. Intellia trades on NASDAQ as NTLA. FDA approval scale: as of mid-2026, Intellia does not have any commercially marketed FDA-approved products. The pipeline is in Phase 2/3 development for the lead candidates.

Intellia Therapeutics portfolio in cross-border NPP scope

Intellia Therapeutics' clinical pipeline includes NTLA-2001 (nexiguran ziclumeran, nex-z), an in vivo CRISPR/Cas9 gene-editing therapy for hereditary transthyretin amyloidosis with polyneuropathy or cardiomyopathy, designed to knock out the TTR gene in hepatocytes and reduce circulating transthyretin protein. NTLA-2001 is in Phase 3 (the MAGNITUDE trial in ATTR cardiomyopathy and the MAGNITUDE-2 trial in ATTR polyneuropathy). The product is partnered with Regeneron and would, if approved, be a one-time intravenous gene-editing treatment - the first in vivo CRISPR therapy of its kind.

NTLA-2002 is an in vivo CRISPR/Cas9 gene-editing therapy for hereditary angioedema (HAE), designed to knock out the KLKB1 gene in hepatocytes and durably reduce plasma kallikrein. NTLA-2002 is in late-stage clinical development with a planned Biologics License Application submission in 2026 based on Phase 2 data showing substantial reduction in HAE attack rates.

Intellia Therapeutics does not currently have any FDA-approved commercial products available through US wholesale specialty distribution. Reserve Meds therefore cannot coordinate Intellia product through standard NPP channels until pipeline candidates receive FDA approval.

For hATTR amyloidosis patients seeking commercially approved therapy, current FDA-approved options include Amvuttra (vutrisiran, Alnylam) and Wainua (eplontersen, Ionis/AstraZeneca) for polyneuropathy, and Vyndamax (tafamidis, Pfizer) for cardiomyopathy. Reserve Meds maintains the Alnylam page for Amvuttra coordination.

Why patients route through cross-border NPP

Cross-border patient interest in Intellia Therapeutics is currently limited to clinical-trial navigation rather than commercial product coordination. The standard cross-border NPP pathway requires an FDA-approved commercial product available through licensed US wholesale distribution. Until NTLA-2002 (HAE) and NTLA-2001 (hATTR) reach FDA approval, Reserve Meds does not coordinate Intellia product.

For families with clinical-trial interest in Intellia pipeline candidates, the appropriate pathway is direct engagement with the trial sites listed on ClinicalTrials.gov and the company's Medical Information group. The MAGNITUDE program in particular has clinical-trial sites across multiple countries and may be accessible to international patients depending on protocol-specific eligibility and site availability.

Once Intellia pipeline candidates receive FDA approval - particularly NTLA-2002 for HAE, which has expected approval activity in the near term - Reserve Meds will activate full cross-border NPP coordination for those products through US wholesale specialty distribution channels.

Common cross-border destinations

Cross-border patient navigation for Intellia Therapeutics clinical-trial participation is inbound to US and other authorised trial sites. Inbound patient interest is primarily from India, the United Arab Emirates, Saudi Arabia, Turkey, and other hATTR or HAE high-prevalence regions.

Manufacturer engagement posture

Reserve Meds does not currently coordinate Intellia Therapeutics commercial product because no Intellia product is currently FDA-approved. We are not affiliated with Intellia Therapeutics. For Intellia medical affairs or future commercial teams interested in cross-border patient pathways once pipeline products receive FDA approval, our BD contact is [email protected].

What Reserve Meds provides

For Intellia Therapeutics clinical-trial navigation, Reserve Meds provides: identification of clinical-trial sites listed on ClinicalTrials.gov; medical record transfer support for trial-site eligibility screening where requested; destination-country regulatory documentation for cross-border medical travel for trial participation; and a dedicated coordinator for the navigation process. We do not provide medical advice on trial selection.

Clinical governance and prescription review

Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.

Supply chain integrity

Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.

Destination-country regulatory pathways

Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.

What to expect through the coordination process

Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.

Not affiliated with the manufacturer

Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.

Privacy and data handling

Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.

Next step for patients

Patients or caregivers interested in cross-border navigation for Intellia Therapeutics clinical-trial participation can begin a navigation request now. For hATTR amyloidosis patients seeking commercially approved therapy, please see our Alnylam Amvuttra page. Start a navigation request ›

Next step for Intellia teams

Intellia Therapeutics medical affairs or future commercial teams interested in international patient pathways can reach our BD team at [email protected]. We will activate full cross-border NPP coordination once Intellia pipeline candidates receive FDA approval.

Reserved for you.